Urine Drug Test Concentrations Up for Fentanyl, Methamphetamine, Cocaine
By Lori Solomon HealthDay Reporter
TUESDAY, Oct. 29, 2024 -- Absolute concentrations of fentanyl, methamphetamine, and cocaine in urine specimens increased from 2013 to 2023, according to a study published online Oct. 24 in JAMA Network Open.
Andrew S. Huhn, Ph.D., from the Johns Hopkins University School of Medicine in Baltimore, and colleagues analyzed urine drug testing (UDT) results to quantify changes in absolute drug exposure concentrations from 2013 to 2023. The analysis included 921,931 unique UDT samples.
The researchers found that the adjusted fentanyl concentration in urine specimens was 38.23 ng/mg creatinine in 2023, up from 4.61 ng/mg in 2013. The adjusted methamphetamine concentration was 3,461.59 ng/mg creatinine in 2023, up from 665.27 ng/mg in 2013. The adjusted cocaine concentration was 1,122.23 ng/mg creatinine in 2023, up from 559.71 ng/mg in 2013. The adjusted heroin concentration was 58.36 ng/mg creatinine in 2023, down from 146.59 ng/mg in 2013. There was variation in drug concentrations across U.S. Census divisions.
"The findings suggest that exposure to these substances, as well as the illicit drug supply, has fundamentally changed in many parts of the United States, highlighting the need to reinforce surveillance initiatives and accelerate efforts to treat individuals with illicitly manufactured fentanyl and/or stimulant exposure," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2025 HealthDay. All rights reserved.
Posted October 2024
Read this next
Declining Childhood Vaccination May Increase Risk for Vaccine-Preventable Infections
WEDNESDAY, April 30, 2025 -- Declining childhood vaccination rates may increase outbreaks of eliminated vaccine-preventable infections within the United States, leading to a...
AACR: Incidence-Based Mortality Dropping for Young Women With Breast Cancer
TUESDAY, April 29, 2025 -- Incidence-based mortality (IBM) declined from 2010 to 2020 among women aged 20 to 49 years diagnosed with breast cancer, according to a study presented...
AACR: Nonsurgical Treatment Feasible for Mismatch Repair-Deficient Tumors
TUESDAY, April 29, 2025 -- A neoadjuvant programmed cell death 1 (PD-1) blockade enables nonoperative management among patients with early-stage mismatch repair-deficient (dMMR)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.